Xiong A, Yao W, Zheng W, Yu Y, et al. Sacituzumab tirumotecan plus pembrolizumab versus pembrolizumab in PD-L1-positive advanced non-small-cell lung cancer (OptiTROP-Lung05): interim analysis of a randomised, open-label, phase 3 trial. Lancet 2026 May 29:S0140-6736(26)00968-2. doi: 10.1016/S0140-6736(26)00968.
PMID: 42214392